Breaking News, Collaborations & Alliances

MilliporeSigma Contributes to Advancing Parkinson’s Research

Makes its immunoassay technology available to the scientific community through support from The Michael J. Fox Foundation for Parkinson's Research.

Author Image

By: Charlie Sternberg

Associate Editor

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, and The Michael J. Fox Foundation for Parkinson’s Research (MJFF), are advancing research aimed at slowing progression of Parkinson’s disease (PD).   Through funding from MJFF’s “Biomarkers to Support Therapeutic Trials Program,” MilliporeSigma’s SMCxPRO immunoassay technology has been used to help detect low levels of a biomarker associated with cell dysfunction in patients. Now, the service is ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters